Project 11 is a coordinated drug discover program that involves the full range of analytical capabilities represented within the Center. It is a continuation of the collaborative efforts of many laboratories that were previously grouped under a general core structure. The novel tropane analogs produced by the vinylcarbenoid chemistry of Dr. Huw Davies will be screened for their neurochemical potency, specificity and behavioral actions in an effort to identify compounds with scientifically interesting properties and/or therapeutic value. Compounds will be screened for their specificity and efficacy at monoamine transporters and for their lipophilicity by Drs. Childers and Bennett. Selected compounds will be characterized for their effects on regional glucose metabolism in Dr. Porrino's laboratory; she will also assess the locomotor stimulant effects on these tropanes and determine their time course. Dr. Smith will examine the effects of selected tropanes on extracellular dopamine and serotonin levels through microdialysis studies. Self-administration studies conducted by Dr. Roberts will examine the relative reinforcing efficacy of specific tropane analogues that will be useful for the analysis of basic neurobiological questions concerning psychostimulant reinforcement and as potential therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
3P50DA006634-08S2
Application #
6218905
Study Section
Project Start
1999-02-01
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106
Siciliano, Cody A; Saha, Kaustuv; Calipari, Erin S et al. (2018) Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation. J Neurosci 38:484-497
Ilyasov, Alexander A; Milligan, Carolanne E; Pharr, Emily P et al. (2018) The Endocannabinoid System and Oligodendrocytes in Health and Disease. Front Neurosci 12:733
Ding, Huiping; Kiguchi, Norikazu; Yasuda, Dennis et al. (2018) A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med 10:
Chen, R; McIntosh, S; Hemby, S E et al. (2018) High and low doses of cocaine intake are differentially regulated by dopamine D2 receptors in the ventral tegmental area and the nucleus accumbens. Neurosci Lett 671:133-139
John, William S; Martin, Thomas J; Solingapuram Sai, Kiran Kumar et al. (2018) Chronic ?9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability. J Pharmacol Exp Ther 364:300-310
Siciliano, Cody A; McIntosh, J Michael; Jones, Sara R et al. (2017) ?6?2 subunit containing nicotinic acetylcholine receptors exert opposing actions on rapid dopamine signaling in the nucleus accumbens of rats with high-versus low-response to novelty. Neuropharmacology 126:281-291
Shaw, Jessica K; Ferris, Mark J; Locke, Jason L et al. (2017) Hypocretin/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine. Addict Biol 22:1695-1705
Siciliano, Cody A; Jones, Sara R (2017) Cocaine Potency at the Dopamine Transporter Tracks Discrete Motivational States During Cocaine Self-Administration. Neuropsychopharmacology 42:1893-1904
Brodnik, Zachary D; Ferris, Mark J; Jones, Sara R et al. (2017) Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition. ACS Chem Neurosci 8:281-289
Fordahl, Steve C; Jones, Sara R (2017) High-Fat-Diet-Induced Deficits in Dopamine Terminal Function Are Reversed by Restoring Insulin Signaling. ACS Chem Neurosci 8:290-299

Showing the most recent 10 out of 310 publications